Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Apellis Pharmaceuticals (NASDAQ:APLS) has been the subject of 15 analyst evaluations over the last three months, showing a range of opinions from bullish to bearish. The average 12-month price target for APLS is now $79.4, up from $67.00, indicating an 18.51% increase. The company has shown remarkable revenue growth of 545.89% as of December 31, 2023, and has a net margin of -60.51%. Despite challenges in ROE and ROA, its debt-to-equity ratio is below industry average, suggesting a healthier balance between debt and equity.
March 27, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has received varied analyst ratings, with an updated average 12-month price target of $79.4, indicating potential growth. The company's significant revenue growth and financial indicators suggest a positive outlook, despite some operational challenges.
The increase in the average price target to $79.4, up from $67.00, suggests analysts are optimistic about Apellis Pharmaceuticals' future performance. The company's impressive revenue growth rate of 545.89% further supports a positive short-term impact on its stock price. However, challenges in ROE and ROA are noted, but the low debt-to-equity ratio mitigates some financial risks, contributing to the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100